Write detailed overview regarding cervical cancer elimination initiative, about global strategy and Indian scenarios. Use tables and flowchart if required.

Reading File

Finding Sources

Searching PubMed

"cervical cancer" AND "elimination" AND "WHO strategy"

Searching the Web

WHO global strategy cervical cancer elimination 90-70-90 targets 2030 India

Reading File

Finding Sources

Searching PubMed

"cervical cancer" AND "India" AND "HPV vaccination" AND elimination

Searching the Web

cervical cancer elimination India CERVAVAC HPV vaccine national program 2023 2024 2025 screening

Reading File

Reading Article

PMID: 40908766

Reading Article

PMID: 42072849

Reading Web Page

https://www.who.int/initiatives/cervical-cancer-elimination-…

Reading File

Searching PubMed

"cervical cancer" AND "India" AND burden GLOBOCAN screening

Searching the Web

India cervical cancer burden 2022 GLOBOCAN statistics incidence mortality HPV prevalence

Cervical Cancer Elimination Initiative: Global Strategy and Indian Scenario

1. Background: Disease Burden

Cervical cancer is the fourth most common cancer in women globally and one of the few cancers with a known, preventable infectious cause - Human Papillomavirus (HPV). Nearly 94% of deaths occur in low- and middle-income countries (LMICs), making it a disease of inequity.

Global Statistics (GLOBOCAN 2022)

Parameter	Global	India
New cases per year	662,301	127,526 (2nd globally)
Deaths per year	348,189	~77,348
Age-standardised incidence rate	14.1/100,000	17.7/100,000
Ranking among women	4th most common cancer	2nd most common cancer
Ranking (age 15-44 yrs)	Top 3 in 149 countries	2nd most common
5-year prevalence (global)	~1.93 million	Significant share
Deaths occurring in LMICs	>85%	Part of LMIC burden

Projected increase by 2030 (if 2022 rates unchanged): 760,082 new cases (+14.8%) and 411,035 deaths (+17.8%). (Wu J et al., J Natl Cancer Cent, 2025)

2. HPV Virology: The Root Cause

HPV infection is detected in >99% of all cervical cancers - Goldman-Cecil Medicine.

HPV Feature	Details
Type classification	>200 strains; ~40 infect the genital tract
Low-risk types (6, 11)	Genital warts
High-risk types	HPV 16, 18 cause 70% of cervical cancers
Additional high-risk	HPV 31, 33, 45, 52, 58 cause ~20% more cases
Transmission	Sexual (genital-genital, genital-oral contact)
Natural clearance	Most infections clear within 1-2 years
Persistent infection	~10% develop persistent HPV; precancer risk
Oncoproteins	E6 (degrades p53), E7 (degrades pRB) - drive carcinogenesis

HPV Prevalence in India (ICO/IARC 2023)

Cytological Group	HPV 16/18 Prevalence
Normal cytology	5.0%
Low-grade cervical lesions	28.2%
High-grade cervical lesions	62.8%
Invasive cervical cancer	83.2%

3. WHO Global Strategy: The 90-70-90 Framework

In May 2018, WHO Director-General issued a global call to action. In August 2020, the World Health Assembly adopted the formal resolution. On 17 November 2020, the strategy was officially launched.

Elimination Threshold

Cervical cancer will be considered eliminated as a public health problem when all countries reach an annual incidence rate of ≤4 cases per 100,000 women.

The 90-70-90 Targets (by 2030)

┌─────────────────────────────────────────────────────────────────┐
│              WHO 90-70-90 TARGETS BY 2030                       │
├──────────────┬──────────────────────────────────────────────────┤
│  PILLAR 1    │  VACCINATION                                      │
│  90%         │  90% of girls fully vaccinated with HPV          │
│              │  vaccine by age 15 years                         │
├──────────────┼──────────────────────────────────────────────────┤
│  PILLAR 2    │  SCREENING                                        │
│  70%         │  70% of women screened with a high-performance   │
│              │  test by age 35 AND again by age 45              │
├──────────────┼──────────────────────────────────────────────────┤
│  PILLAR 3    │  TREATMENT                                        │
│  90%         │  90% of women with pre-cancer treated            │
│              │  90% of women with invasive cancer managed       │
└──────────────┴──────────────────────────────────────────────────┘

Projected Benefits of Achieving 90-70-90

Timeframe	Outcome
By 2030	300,000 cumulative deaths averted
By 2045	42% reduction in cervical cancer incidence
By 2070	>14 million cumulative deaths averted
By 2120	>74 million new cases averted; 97% reduction in incidence
By 2120	>62 million cumulative deaths averted

4. Three-Pillar Strategy: Detailed Framework

FLOWCHART: Cervical Cancer Elimination Pathway

        ADOLESCENT GIRL (9-14 yrs)
                    │
                    ▼
        ┌───────────────────────┐
        │  PILLAR 1: VACCINATION │
        │  HPV vaccine (1 or 2  │
        │  doses depending on   │
        │  national schedule)   │
        └───────────┬───────────┘
                    │
                    ▼
        ADULT WOMAN (35 years old)
                    │
                    ▼
        ┌───────────────────────┐
        │  PILLAR 2: SCREENING  │
        │  HPV DNA test /       │
        │  VIA / Pap smear      │
        └───────────┬───────────┘
                    │
          ┌─────────┴──────────┐
          ▼                    ▼
    SCREEN NEGATIVE      SCREEN POSITIVE
    (repeat at 45)           │
                             ▼
                   ┌──────────────────┐
                   │    TRIAGE TEST   │
                   │ Colposcopy/VIA   │
                   └─────────┬────────┘
                             │
               ┌─────────────┴──────────────┐
               ▼                            ▼
         PRE-CANCER                  INVASIVE CANCER
               │                            │
               ▼                            ▼
        ┌──────────────┐          ┌──────────────────────┐
        │  PILLAR 3:   │          │    PILLAR 3:          │
        │  TREATMENT   │          │    MANAGEMENT         │
        │  Cryotherapy │          │    Surgery/RT/ChemoRT │
        │  LEEP/CKC    │          │    Immunotherapy      │
        │  Ablation    │          │    Palliative care    │
        └──────────────┘          └──────────────────────┘

Pillar 1 - HPV Vaccination

Feature	Details
Primary target	Girls aged 9-14 years (pre-sexual debut)
Available vaccines	Bivalent (Cervarix - HPV 16/18); Quadrivalent (Gardasil, CERVAVAC - HPV 6/11/16/18); Nonavalent (Gardasil-9 - HPV 6/11/16/18/31/33/45/52/58)
Dosing schedules	1-dose (60 countries); 2-dose (80 countries); 3-dose (for older/immunocompromised)
Countries with national programs	>140 countries as of 2025
Cancer prevention	70-90% of cervical cancers preventable depending on vaccine type
WHO recommendation	1-2 doses for girls 9-14; 2-3 doses for 15+ or immunocompromised

Pillar 2 - Screening

Method	Performance	Context
HPV DNA testing	Gold standard; high sensitivity (~88%); specificity ~75%	Preferred by WHO for primary screening
Self-sampling	Non-inferior to clinician-collected; improves access	Expanding in LMICs
VIA (Visual Inspection with Acetic Acid)	Low-cost, point-of-care	Suitable for low-resource settings
Pap smear (cytology)	Established; requires lab infrastructure	High-resource settings
AI-assisted tools	Emerging; enhances diagnostic accuracy	Portable devices being developed
Frequency	Twice in a lifetime minimum (at 35 and 45) per WHO for LMICs	More frequent in HIC guidelines

Pillar 3 - Treatment

Stage	Treatment Options
Pre-cancerous lesions (CIN 2/3)	Cryotherapy, LEEP (Loop Electrosurgical Excision Procedure), cold knife conization (CKC), ablation
Stage I (early invasive)	Surgery (radical hysterectomy) or radiotherapy; fertility-sparing options in very early stages
Stage II-III	Concurrent chemoradiotherapy (cisplatin-based)
Stage IV / Recurrent	Chemoradiotherapy + immunotherapy (pembrolizumab, bevacizumab); palliative care
Emerging	Sentinel lymph node biopsy (alternative to full lymphadenectomy); minimally invasive surgery for small tumors; robotic-assisted

5. Regional Progress and Disparities (2026 Systematic Review)

Based on Luca DC et al., Diagnostics, 2026 (PMID: 42072849):

World Region	Status
High-income countries (Western Europe, Australia, North America)	On track - organized vaccination and screening programs, favorable outcomes
Eastern Europe	Below WHO targets - lower vaccination uptake, limited screening
Parts of Asia (incl. South Asia)	Mixed - gaps in all three pillars
Sub-Saharan Africa	Most challenged - high burden, limited infrastructure
Latin America	Variable - some countries progressing, others lagging

Key barriers identified:

Inequalities in healthcare access
Differences in program organization
Limited comparability of national data
Vaccine hesitancy and awareness gaps

6. India-Specific Scenario

Epidemiological Burden

Indicator	India (2022-2023)
New cases per year	127,526 (GLOBOCAN 2022) / 123,907 (ICO/IARC 2023)
Deaths per year	~77,348
Cancer ranking in women	2nd (after breast cancer)
Ranking in women aged 15-44	2nd most common
ASR incidence	17.7-18.0 per 100,000 women
ASR mortality	~11.4-11.7 per 100,000 women
Population at risk (women ≥15 yrs)	~511.4 million
HPV 16/18 contribution	83.2% of invasive cervical cancers
Late-stage presentation	Majority diagnosed at Stage II-IV

India's HPV Vaccine Journey

Milestone	Year	Details
Gardasil (qHPV) available	~2008	Imported; high cost (~₹3,000-4,000/dose)
Cervarix (bivalent) available	~2009	Imported
CERVAVAC approved	2022-2023	India's first indigenous qHPV vaccine (Serum Institute of India); covers HPV 6, 11, 16, 18
CERVAVAC introduction to NIP	2023 (Budget announcement)	₹200-400/dose - drastically reduced cost
National Immunization Program (NIP) launch	February 2023	Girls aged 9-14 years; school-based
CERVAVAC indication	Females 9-26 years	Prevention of cervical, vulvar, vaginal, anal cancers and genital warts

CERVAVAC significance: Being manufactured in India at a fraction of the cost of imported vaccines makes it a game-changer for achieving the 90% vaccination target in a country with 511 million women at risk.

India's Screening Landscape

Aspect	Current Status	Challenges
Screening coverage	<30% of eligible women ever screened	Far below the 70% WHO target
Primary method	VIA/VILI at district hospitals and health centers	Limited lab infrastructure for cytology in rural areas
HPV DNA testing	Being scaled up under NHM	Cost and logistics barriers
Pap smear	Available at higher centers	Requires cytopathology infrastructure
National program	NHM's Population-Based Cancer Screening (PBCS)	Focus on VIA/Pap; HPV testing being added
Urban-rural divide	Stark disparity	Rural women least screened; highest mortality

Government of India Initiatives

Program/Policy	Details
National Cancer Control Programme (NCCP)	Established cancer detection and treatment network
Population-Based Cancer Screening (NHM)	Screen oral, breast, and cervical cancer; target women 30-65 yrs
CERVAVAC in NIP (2023)	Included in Universal Immunization Programme (UIP)
Ayushman Bharat - PM-JAY	Covers cancer treatment costs for eligible beneficiaries
District Cancer Care Programme	Network of District Hospitals for early detection
National Guidelines (Ministry of Health)	Formulated guidelines for screening and management - (Mehrotra R, Yadav K, 2022, PMID: 34977333)
Parliamentary Committee recommendation	Scale up screening, region-specific awareness, NGO involvement

India vs. 90-70-90 Targets: Current Status

TARGET          CURRENT STATUS (India ~2024-26)   GAP
─────────────────────────────────────────────────────────
Vaccination     ~30-40% HPV vaccine coverage       Large gap to 90%
(girls by 15)   (estimated; CERVAVAC now in NIP)   Programs ramping up

Screening       <30% ever screened                 Very large gap to 70%
(by 35 & 45)    (PBCS ongoing; HPV tests limited)  Urgent scale-up needed

Treatment       Variable; late-stage diagnosis      Quality and access
(90% treated)   limits effective treatment         gaps remain

Key Challenges for India

Scale - Vaccinating millions of girls annually across 28 states with variable health infrastructure
Awareness - Social stigma, low cancer literacy, cultural barriers
Rural access - Cold chain maintenance, healthcare worker shortages in remote areas
Late-stage diagnosis - Most patients present with advanced disease, limiting cure rates
Healthcare professional training - Inadequate colposcopy and LEEP skills at district level
Data quality - No robust population-based cancer registry covering all of India
Funding - Sustained funding for vaccine procurement, screening kits, and treatment

7. Innovations Advancing Elimination (2025 FIGO Update)

Based on Bhatla N et al., Int J Gynaecol Obstet, 2025 (PMID: 40908766):

Domain	Innovation
Vaccination	Single-dose schedules now implemented in 60 countries; nonavalent vaccines covering 9 HPV types
Screening	Self-sampling HPV tests (non-inferior to clinician-collected); portable screening and treatment devices; AI-enhanced interpretation
Diagnosis	Immunohistochemistry and receptor assays for better diagnostic accuracy
Surgery	Conservative fertility-sparing surgery for very early-stage disease; minimally invasive for small tumors; sentinel lymph node evaluation replacing full lymphadenectomy
Medical treatment	Pembrolizumab (anti-PD-1) immunotherapy for recurrent/metastatic disease; bevacizumab in combination

8. Evidence from Real-World Programs

A striking example of what vaccination can achieve: Sasieni P & Falcaro M, Lancet, 2026 (PMID: 42309117) analyzed England data (2001-2024) and showed significant cervical cancer mortality reductions following HPV vaccination - demonstrating that the elimination pathway is scientifically achievable.

9. Way Forward: India's Path to Elimination

FLOWCHART: India's Strategic Roadmap

┌─────────────────────────────────────────────────────────┐
│              INDIA CERVICAL CANCER ELIMINATION           │
│              STRATEGIC ROADMAP                          │
└─────────────────────────────────────────────────────────┘
                          │
          ┌───────────────┼──────────────────┐
          ▼               ▼                  ▼
  ┌──────────────┐ ┌──────────────┐  ┌──────────────────┐
  │ VACCINATION  │ │  SCREENING   │  │    TREATMENT     │
  │              │ │              │  │                  │
  │ CERVAVAC in  │ │ Scale HPV    │  │ Upgrade district │
  │ UIP for      │ │ DNA testing  │  │ cancer centers   │
  │ girls 9-14   │ │ nationwide   │  │                  │
  │              │ │              │  │ Train surgeons   │
  │ Catch-up     │ │ Integrate    │  │ in LEEP, radical │
  │ vaccination  │ │ with ASHA/   │  │ surgery          │
  │ 15-26 yrs    │ │ Anganwadi    │  │                  │
  │              │ │ workers      │  │ PM-JAY for       │
  │ School-based │ │              │  │ treatment costs  │
  │ delivery     │ │ AI-assisted  │  │                  │
  │              │ │ portable VIA │  │ Palliative care  │
  │ Awareness &  │ │ devices      │  │ network          │
  │ demand gen   │ │              │  │                  │
  └──────────────┘ └──────────────┘  └──────────────────┘
          │               │                  │
          └───────────────┼──────────────────┘
                          ▼
              ┌───────────────────────┐
              │  ENABLING ENVIRONMENT │
              │ - Registry & data     │
              │ - NGO partnerships    │
              │ - Community awareness │
              │ - Healthcare training │
              │ - Funding commitment  │
              └───────────────────────┘
                          │
                          ▼
              ┌───────────────────────┐
              │  TARGET: ≤4 cases per │
              │  100,000 women        │
              │  (Elimination)        │
              └───────────────────────┘

Summary Recommendations for India

Priority	Action	Responsible Entity
1	Achieve 90% HPV vaccine coverage for girls 9-14 via school-based UIP	MoHFW, State Health Depts
2	Scale HPV DNA testing to all district hospitals under NHM	NHM, ICMR
3	Train frontline workers (ASHA, ANM) in VIA and referral pathways	NHM, medical colleges
4	Establish LEEP/colposcopy services at every district hospital	MoHFW
5	Integrate cervical cancer screening into women's health platforms	NACO, NHSRC
6	Region-specific awareness campaigns targeting rural women	State health depts, NGOs
7	Utilize PM-JAY for cancer treatment coverage	NITI Aayog, Insurance
8	Establish national cancer registry for all districts	NCDIR, ICMR
9	Introduce gender-neutral vaccination (boys) long-term	Advisory committee
10	Leverage AI tools for portable, low-cost screening in remote areas	BIRAC, startups

10. Summary Table: Global vs. India at a Glance

Parameter	Global Target (2030)	Global Status	India Target (2030)	India Status
Vaccination coverage (girls)	90% by age 15	~67-70% countries with NIP	90%	~30-40% (CERVAVAC just launched)
Screening coverage (women)	70% by 35 & 45	Variable; many LMICs <30%	70%	<30%
Treatment coverage	90%	Good in high-income; poor in LMICs	90%	Variable; rural gaps significant
Incidence target	≤4/100,000 women	Not yet achieved globally	≤4/100,000 women	Currently 17.7/100,000
Countries with HPV in NIP	-	>140 countries	India joined 2023	Active; scaling up

Key Sources

WHO Global Strategy for Cervical Cancer Elimination (2020) - the foundational document
WHO Cervical Cancer Elimination Initiative
Bhatla N et al. - Cancer of the cervix uteri: 2025 update. PMID: 40908766
Luca DC et al. - Global progress toward cervical cancer elimination (Systematic Review 2026). PMID: 42072849
Wu J et al. - Global burden of cervical cancer based on GLOBOCAN 2022. PMID: 40693230
Mehrotra R, Yadav K - Govt of India Guidelines for screening and management. PMID: 34977333
ICO/IARC HPV Information Centre, India Fact Sheet 2023
GLOBOCAN 2022, India Fact Sheet
Goldman-Cecil Medicine (26th Edition) - Cervical Cancer chapter
Berek & Novak's Gynecology - Cervical Cancer chapter

This is a shared conversation. Sign in to Orris to start your own chat.